Cargando…

Effects of Ranibizumab and Aflibercept on Human Müller Cells and Photoreceptors under Stress Conditions

Anti-vascular endothelial growth factor (VEGF) therapy has revolutionized the treatment of retinal vascular diseases. However, constitutive VEGF also acts as a trophic factor on retinal non-vascular cells. We have studied the effects of aflibercept and ranibizumab on human Müller cells and photorece...

Descripción completa

Detalles Bibliográficos
Autores principales:	Shen, Weiyong, Yau, Belinda, Lee, So-Ra, Zhu, Ling, Yam, Michelle, Gillies, Mark C.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	MDPI 2017
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5372549/ https://www.ncbi.nlm.nih.gov/pubmed/28257068 http://dx.doi.org/10.3390/ijms18030533

Ejemplares similares

Involvement of NT3 and P75(NTR) in photoreceptor degeneration following selective Müller cell ablation
por: Shen, Weiyong, et al.
Publicado: (2013)

Inhibiting the activation of MAPK (ERK1/2) in stressed Müller cells prevents photoreceptor degeneration
por: Zeng, Shaoxue, et al.
Publicado: (2022)

Differential expression of microRNAs in retinal vasculopathy caused by selective Müller cell disruption
por: Chung, Sook Hyun, et al.
Publicado: (2016)

Profiling of MicroRNAs Involved in Retinal Degeneration Caused by Selective Müller Cell Ablation
por: Chung, Sook Hyun, et al.
Publicado: (2015)

Conditional Müller Cell Ablation Leads to Retinal Iron Accumulation
por: Baumann, Bailey, et al.
Publicado: (2017)

Intravitreal aflibercept and ranibizumab for pachychoroid neovasculopathy
por: Jung, Byung Ju, et al.
Publicado: (2019)

Assessment of mouse VEGF neutralization by ranibizumab and aflibercept
por: Ichiyama, Yusuke, et al.
Publicado: (2022)

Effects of switching from ranibizumab to aflibercept in eyes with exudative age-related macular degeneration
por: Barthelmes, Daniel, et al.
Publicado: (2016)

SYSTEMIC PHARMACOKINETICS AND PHARMACODYNAMICS OF INTRAVITREAL AFLIBERCEPT, BEVACIZUMAB, AND RANIBIZUMAB
por: Avery, Robert L., et al.
Publicado: (2017)

Transketolase in human Müller cells is critical to resist light stress through the pentose phosphate and NRF2 pathways
por: Chen, Yingying, et al.
Publicado: (2022)

Human macular Müller cells rely more on serine biosynthesis to combat oxidative stress than those from the periphery
por: Zhang, Ting, et al.
Publicado: (2019)

Cone photoreceptors transfer damaged mitochondria to Müller glia
por: Hutto, Rachel A., et al.
Publicado: (2023)

Comparison of Intravitreal Aflibercept and Ranibizumab following Initial Treatment with Ranibizumab in Persistent Diabetic Macular Edema
por: Demircan, Ali, et al.
Publicado: (2018)

Pattern of adverse events induced by aflibercept and ranibizumab: A nationwide spontaneous adverse event reporting database, 2007–2016
por: Ha, Dongmun, et al.
Publicado: (2019)

Comparison of Outcomes and Costs of Ranibizumab and Aflibercept Treatment in Real-Life
por: Schmid, Martin K., et al.
Publicado: (2015)

Aflibercept versus ranibizumab for treating persistent diabetic macular oedema
por: ROA Vandekerckhove, Kristof
Publicado: (2015)

Conversion to aflibercept for diabetic macular edema unresponsive to ranibizumab or bevacizumab
por: Lim, Laurence S, et al.
Publicado: (2015)

Formulation Stabilization and Disaggregation of Bevacizumab, Ranibizumab and Aflibercept in Dilute Solutions
por: Giannos, Steven A., et al.
Publicado: (2018)

Ranibizumab non-response in pachychoroid neovasculopathy: Effects of switching to aflibercept
por: Schworm, Benedikt, et al.
Publicado: (2020)

Faricimab for Diabetic Macular Edema in Patients Refractory to Ranibizumab or Aflibercept
por: Ohara, Hiromi, et al.
Publicado: (2023)

Selective knockdown of hexokinase 2 in rods leads to age-related photoreceptor degeneration and retinal metabolic remodeling
por: Zhang, Rui, et al.
Publicado: (2020)

Real Life Multicenter Comparison of 24-Month Outcomes of Anti-VEGF Therapy in Diabetic Macular Edema in Turkey: Ranibizumab vs. Aflibercept vs. Ranibizumab-Aflibercept Switch
por: Kucukevcilioglu, Murat, et al.
Publicado: (2023)

Neural and Müller glial adaptation of the retina to photoreceptor degeneration
por: Leinonen, Henri O., et al.
Publicado: (2022)

Intravitreal aflibercept for polypoidal choroidal vasculopathy after developing ranibizumab tachyphylaxis
por: Miura, Masahiro, et al.
Publicado: (2013)

Effects of a Single Intravitreal Injection of Aflibercept and Ranibizumab on Glomeruli of Monkeys
por: Tschulakow, Alexander, et al.
Publicado: (2014)

Aflibercept in refractory wet AMD treated with ranibizumab: Anatomical and visual outcome
por: Abou-Ltaif, Sleiman
Publicado: (2016)

Effects of Ranibizumab, Bevacizumab, and Aflibercept on Senescent Retinal Pigment Epithelial Cells
por: Chae, Jae-Byoung, et al.
Publicado: (2018)

Acquired perforating collagenosis associated with ranibizumab injection and succesfully switched to aflibercept
por: Kanra, Ayse Yagmur, et al.
Publicado: (2018)

Intravitreal aflibercept versus intravitreal ranibizumab for the treatment of diabetic macular edema
por: Fouda, Sameh Mosaad, et al.
Publicado: (2017)

Comparisons of Efficacy of Intravitreal Aflibercept and Ranibizumab in Eyes with Diabetic Macular Edema
por: Shimizu, Norihiro, et al.
Publicado: (2017)

Assessment of Patient Pain Experience During Intravitreal Ranibizumab and Aflibercept Injection
por: Bilgin, Burak, et al.
Publicado: (2019)

THREE-YEAR TREATMENT OUTCOMES OF AFLIBERCEPT VERSUS RANIBIZUMAB FOR DIABETIC MACULAR EDEMA: Data from the Fight Retinal Blindness! Registry
por: Gabrielle, Pierre-Henry, et al.
Publicado: (2022)

12‐month outcomes of ranibizumab versus aflibercept for macular oedema in central retinal vein occlusion: data from the FRB! registry
por: Niedzwiecki, Mateusz, et al.
Publicado: (2021)

Ranibizumab treatment history as predictor of the switch-response to aflibercept: evidence for drug tolerance
por: Dirani, Ali, et al.
Publicado: (2018)

Outcomes and costs of Ranibizumab and Aflibercept treatment in a health-service research context
por: Schmid, Martin K., et al.
Publicado: (2018)

The Effects of Intravitreal Ranibizumab, Aflibercept or Dexamethasone Implant Injections on Intraocular Pressure Changes
por: Karakurt, Yucel, et al.
Publicado: (2018)

Switching to Aflibercept in Diabetic Macular Edema Not Responding to Ranibizumab and/or Intravitreal Dexamethasone Implant
por: Herbaut, Antoine, et al.
Publicado: (2017)

Hydrodynamic Radii of Ranibizumab, Aflibercept and Bevacizumab Measured by Time-Resolved Phosphorescence Anisotropy
por: Hirvonen, Liisa M., et al.
Publicado: (2016)

Switch to aflibercept or ranibizumab after initial treatment with bevacizumab in eyes with neovascular AMD
por: Waizel, Maria, et al.
Publicado: (2017)

Evaluation of ranibizumab and aflibercept for the treatment of diabetic macular edema in daily clinical practice
por: Plaza-Ramos, Pablo, et al.
Publicado: (2019)

Cannot write session to /tmp/vufind_sessions/sess_ral5opsr1s10ies1fp8kneku5a